Results of a previous phase 0 study showed substantial inhibition of PARP activity in tumor biopsies collected 3–6 h after dosing in 3 subjects who received a single dose of 25 mg veliparib (92, 95, and 100 %) [22]. This evidence concerns the gene PARP1 and neoplasm.